Skip to content



Page 1 of 32

  1. Content type: Research article

    The pancreatic cancer vaccine, GVAX, induces novel lymphoid aggregates in the otherwise immune quiescent pancreatic ductal adenocarcinoma (PDAC). GVAX also upregulates the PD-1/PD-L1 pathway, and a pre-clinica...

    Authors: May Tun Saung, Stephen Muth, Ding Ding, Dwayne L. Thomas II, Alex B. Blair, Takahiro Tsujikawa, Lisa Coussens, Elizabeth M. Jaffee and Lei Zheng

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:118

    Published on:

  2. Content type: Short report

    Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML re...

    Authors: Regina Jitschin, Domenica Saul, Martina Braun, Sehmus Tohumeken, Simon Völkl, Roman Kischel, Michael Lutteropp, Cedric Dos Santos, Andreas Mackensen and Dimitrios Mougiakakos

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:116

    Published on:

  3. Content type: Research article

    Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination w...

    Authors: Ahmad Tarhini, Yan Lin, Huang Lin, Zahra Rahman, Priyanka Vallabhaneni, Prateek Mendiratta, James F. Pingpank, Matthew P. Holtzman, Erik C. Yusko, Julie A. Rytlewski, Uma N. M. Rao, Robert L. Ferris and John M. Kirkwood

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:112

    Published on:

  4. Content type: Research article

    We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC).

    Authors: Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebreck, Vijay Kasturi, Vikram Chand and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:111

    Published on:

  5. Content type: Research article

    Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carc...

    Authors: Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang and Hans J Hammers

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:109

    Published on:

  6. Content type: Position article and guidelines

    To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments.

    Authors: Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham and Michael A. Postow

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:108

    Published on:

  7. Content type: Research article

    Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking.

    Authors: Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia and Brian I. Rini

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:107

    Published on:

  8. Content type: Research article

    Several studies have established a correlation between the VEGF–VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (R...

    Authors: Yasuko Tada, Yosuke Togashi, Daisuke Kotani, Takeshi Kuwata, Eichi Sato, Akihito Kawazoe, Toshihiko Doi, Hisashi Wada, Hiroyoshi Nishikawa and Kohei Shitara

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:106

    Published on:

  9. Content type: Case report

    The use of immune checkpoint inhibitors is increasing in cancer therapy today. It is critical that treatment teams become familiar with the organ systems potentially impacted by immune-related adverse events a...

    Authors: Kendall F. Moseley, Jarushka Naidoo, Clifton O. Bingham, Michael A. Carducci, Patrick M. Forde, Geoffrey T. Gibney, Evan J. Lipson, Ami A. Shah, William H. Sharfman and Laura C. Cappelli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:104

    Published on:

  10. Content type: Research article

    Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side e...

    Authors: Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Junsheng Ma, Roland L Bassett Jr, Noha Abdel-Wahab, Jaime Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:103

    Published on:

  11. Content type: Research article

    Immunoscore, as a prognostic tool defined to quantify in situ immune cell infiltrates, appears to be superior to the TNM staging system. In esophageal squamous cell carcinoma (ESCC), no immunoscore has been es...

    Authors: Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Yu Wang, Zhongyi Fan, Shengsheng Yang and Shunchang Jiao

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:100

    Published on:

  12. Content type: Research article

    Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incide...

    Authors: Bin Zhao, Hong Zhao and Jiaxin Zhao

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:101

    Published on:

  13. Content type: Review

    The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over...

    Authors: Maartje W. Rohaan, Joost H. van den Berg, Pia Kvistborg and John B. A. G. Haanen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:102

    Published on:

  14. Content type: Research article

    We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified.

    Authors: Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:99

    Published on:

  15. Content type: Research article

    Women diagnosed with breast cancer within 5 years postpartum (PPBC) have poorer prognosis than age matched nulliparous women, even after controlling for clinical variables known to impact disease outcomes. Thr...

    Authors: Nathan D. Pennock, Holly A. Martinson, Qiuchen Guo, Courtney B. Betts, Sonali Jindal, Takahiro Tsujikawa, Lisa M. Coussens, Virginia F. Borges and Pepper Schedin

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:98

    Published on:

  16. Content type: Case report

    Malignant angiomyolipoma is an uncommon tumor of the class of perivasciular epithelioid cell neoplasms (PEComas). These tumors are characteristically driven by deleterious mutations in the tumor suppressors TSC1 ...

    Authors: Michael Lattanzi, Fang-Ming Deng, Luis A. Chiriboga, Alisa N. Femia, Shane A. Meehan, Gopa Iyer, Martin H. Voss, Yuliya Sundatova, William C. Huang and Arjun V. Balar

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:97

    Published on:

  17. Content type: Short report

    Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines ...

    Authors: Javier Rodriguez, Eduardo Castañón, Jose Luis Perez-Gracia, Inmaculada Rodriguez, Antonio Viudez, Carlos Alfaro, Carmen Oñate, Guiomar Perez, Fernando Rotellar, Susana Inogés, Ascensión López-Diaz de Cerio, Leyre Resano, Mariano Ponz-Sarvise, Maria E. Rodriguez-Ruiz, Ana Chopitea, Ruth Vera…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:96

    Published on:

  18. Content type: Research article

    This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting gluco...

    Authors: Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M. LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Courtney Beers, Gataree Ngarmchamnanrith and Patrick Schöffski

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:93

    Published on:

  19. Content type: Research article

    Immune checkpoint inhibitors (ICPI) are efficacious treatments for advanced malignancies but can result in immune mediated diarrhea and colitis (IDC). Currently, the guidelines for the treatment of IDC depend ...

    Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Wenyi Luo, Wei Qiao, Gottumukkala S. Raju and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:95

    Published on:

  20. Content type: Case report

    Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy.

    Authors: Michael J. Wagner, Robert W. Ricciotti, Jose Mantilla, Elizabeth T. Loggers, Seth M. Pollack and Lee D. Cranmer

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:94

    Published on:

  21. Content type: Correction

    After publication of this article [1], it was noticed that 3 authors were missed from the author list.

    Authors: Benjamin O. Tschumi, Nina Dumauthioz, Bastien Marti, Lianjun Zhang, Evripidis Lanitis, Melita Irving, Pascal Schneider, Jean-Pierre Mach, George Coukos, Pedro Romero and Alena Donda

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:92

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:71

  22. Content type: Research article

    Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk d...

    Authors: Philip Friedlander, Kevin Wood, Karl Wassmann, Alan M. Christenfeld, Nina Bhardwaj and William K. Oh

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:90

    Published on:

  23. Content type: Clinical trials monitor

    Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefi...

    Authors: Jason M. Redman, Seth M. Steinberg and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:91

    Published on:

  24. Content type: Research article

    Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the ...

    Authors: Guozhu Xie, Tan Cheng, Jie Lin, Lanfang Zhang, Jieling Zheng, Ying Liu, Guobo Xie, Baiyao Wang and Yawei Yuan

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:88

    Published on:

  25. Content type: Case report

    The development of a new lesion in a patient with a complete remission to anti-PD-1 therapy is highly concerning for a drug resistant escape lesion. Here, we present a case of a 62-year-old patient with chemot...

    Authors: Johannes C. Melms, Rohit Thummalapalli, Kristin Shaw, Huihui Ye, Leo Tsai, Rupal S. Bhatt and Benjamin Izar

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:89

    Published on:

  26. Content type: Review

    CD8+ T lymphocytes are the major anti-tumor effector cells. Most cancer immunotherapeutic approaches seek to amplify cytotoxic T lymphocytes (CTL) specific to malignant cells. A recently identified subpopulation ...

    Authors: Fathia Mami-Chouaib, Charlotte Blanc, Stéphanie Corgnac, Sophie Hans, Ines Malenica, Clémence Granier, Isabelle Tihy and Eric Tartour

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:87

    Published on:

  27. Content type: Review

    Cancer surgery is necessary and life-saving. However, the majority of patients develop postoperative recurrence and metastasis, which are the main causes of cancer-related deaths. The postoperative stress resp...

    Authors: Orneala Bakos, Christine Lawson, Samuel Rouleau and Lee-Hwa Tai

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:86

    Published on:

  28. Content type: Case report

    The development of pulmonary immune-related adverse events (irAEs) in patients undergoing PD-(L)1 targeted checkpoint inhibitors are rare, but may be life-threatening. While many published articles and guideli...

    Authors: Guacimara Ortega Sanchez, Kathleen Jahn, Spasenija Savic, Alfred Zippelius and Heinz Läubli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:85

    Published on:

  29. Content type: Case report

    Immune checkpoint inhibitors (ICIs) are the treatment of choice for several cancers and can be associated with remarkable clinical benefit, but can also cause serious immune-related adverse events (irAEs). Man...

    Authors: Jacob Appelbaum, David Wells, Joseph B. Hiatt, Gideon Steinbach, F. Marc Stewart, Hannah Thomas, Paul Nghiem, Raj P. Kapur, John A. Thompson and Shailender Bhatia

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:82

    Published on:

  30. Content type: Case report

    PD-1 and CTLA-4 inhibitors are associated with several adverse events including a spectrum of immune-related adverse effects (irAEs). Neurologic irAEs are uncommon occurrences with varied presentations. We des...

    Authors: Christine A. Garcia, Alex El-Ali, Tanya J. Rath, Lydia C. Contis, Vikram Gorantla, Jan Drappatz and Diwakar Davar

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:83

    Published on:

  31. Content type: Research article

    Low absolute lymphocyte count (ALC) has previously been established as a marker of poor prognosis in multiple cancer types. There is growing evidence that ALC may also be associated with response to immunother...

    Authors: Won Jin Ho, Mark Yarchoan, Alex Hopkins, Ranee Mehra, Stuart Grossman and Hyunseok Kang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:84

    Published on:

  32. Content type: Clinical trials monitor

    With numerous and fast approvals of different agents including immune checkpoint inhibitors, monoclonal antibodies, or chimeric antigen receptor (CAR) T-cell therapy, immunotherapy is now an established form o...

    Authors: Nolan A. Wages, Cody Chiuzan and Katherine S. Panageas

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:81

    Published on:

  33. Content type: Commentary

    An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously trea...

    Authors: Mark R. Albertini

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:80

    Published on:

  34. Content type: Commentary

    Immunotherapy is rapidly becoming the fourth arm of cancer treatment, and breakthrough successes have been observed in multiple malignancies. However, despite the potential for impressive anti-tumor effects, o...

    Authors: Robert J. Canter and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:79

    Published on:

  35. Content type: Research article

    In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. H...

    Authors: Neil S. Forbes, Robert S. Coffin, Liang Deng, Laura Evgin, Steve Fiering, Matthew Giacalone, Claudia Gravekamp, James L. Gulley, Hal Gunn, Robert M. Hoffman, Balveen Kaur, Ke Liu, Herbert Kim Lyerly, Ariel E. Marciscano, Eddie Moradian, Sheryl Ruppel…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:78

    Published on:

  36. Content type: Research article

    Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafe...

    Authors: Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung and David H. Lawson

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:76

    Published on:

  37. Content type: Position article and guidelines

    Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefi...

    Authors: Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:75

    Published on:

  38. Content type: Research article

    Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint i...

    Authors: Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò and Paolo Antonio Ascierto

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:74

    Published on:

  39. Content type: Case report

    Use of anti-programmed cell death-1 (anti-PD-1) has been successful in treating many types of cancers. Despite its promising efficacy, immune-related adverse events are still a major concern. Immune-related ca...

    Authors: Chien-Yi Hsu, Yu-Wen Su and San-Chi Chen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:72

    Published on:

  40. Content type: Case report

    Treatment of metastatic melanoma patients with immune checkpoint inhibitors is an important standard of care. Side effects are due to immune activation, can affect virtually all organ systems, and are occasion...

    Authors: Andrew Hantel, Brooke Gabster, Jason X. Cheng, Harvey Golomb and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:73

    Published on:

  41. Content type: Research article

    Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are attractive targets for TCR gene therapy of cancer. The majority of such mutations are patient-sp...

    Authors: Vanessa M. Tubb, Deborah S. Schrikkema, Nathan P. Croft, Anthony W. Purcell, Carsten Linnemann, Manon R. Freriks, Frederick Chen, Heather M. Long, Steven P. Lee and Gavin M. Bendle

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:70

    Published on:

  42. Content type: Short report

    Adoptive transfer of T cells transduced with Chimeric Antigen Receptors (CAR) are now FDA-approved for the treatment of B-cell malignancies. Yet, the functionality of the endogenous TCR in CART cells has not b...

    Authors: Benjamin O. Tschumi, Nina Dumauthioz, Bastien Marti, Lianjun Zhang, Pascal Schneider, Jean-Pierre Mach, Pedro Romero and Alena Donda

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:71

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2018 6:92

  43. Content type: Research article

    Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acqui...

    Authors: Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross and Maria E. Cabanillas

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:68

    Published on:

  44. Content type: Review

    Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option ac...

    Authors: Paolo A. Ascierto, James Brugarolas, Luigi Buonaguro, Lisa H. Butterfield, David Carbone, Bruno Daniele, Robert Ferris, Bernard A. Fox, Jérôme Galon, Cesare Gridelli, Howard L. Kaufman, Christopher A. Klebanoff, Ignacio Melero, Paul Nathan, Chrystal M. Paulos, Marco Ruella…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:69

    Published on:

2017 Journal Metrics